Drug Delivery - Informa Connect

@DrugDeliveryIC

The official twitter account for the Informa Connect Drug Delivery portfolio. Your home for all things drug delivery partnerships.

Vrijeme pridruživanja: srpanj 2009.

Tweetovi

Blokirali ste korisnika/cu @DrugDeliveryIC

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @DrugDeliveryIC

  1. Prikvačeni tweet

    Share your expertise on all things & with others! Also, join our LinkedIn community:

    Poništi
  2. Poništi
  3. How can you avoid new therapies being derailed by regulatory processes? This whitepaper presents successful strategies for peptide, oligonucleotide and mRNA therapeutic products.

    Poništi
  4. Poništi
  5. Poništi
  6. How can you navigate the regulatory maze to get peptide, oligonucleotide and mRNA therapies to market? This whitepaper presents successful strategies & case studies.

    Poništi
  7. Poništi
  8. Heidelberg-based have created tumor-targeted oncolytic virus vaccines using encoded bispecific T-cell engagers. In this recorded webinar, Christine Engeland, MD, PhD explains their journey.

    Poništi
  9. The high costs of cell therapy puts it out of reach for many cancer patients. How can it be made more affordable? We asked three industry experts

    Poništi
  10. Poništi
  11. Applying for marketing authorisation in new global drug markets can be easier said than done. This whitepaper looks at the regulatory challenges in eSubmissions around the world.

    Poništi
  12. What’s the recipe for getting peptide, oligonucleotide and mRNA treatments approved? This whitepaper explores how to navigate the current regulatory frameworks.

    Poništi
  13. What’s delaying the global harmonisation of eSubmissions for marketing authorisation? This whitepaper examines the regulatory developments and ongoing challenges around the world.

    Poništi
  14. Poništi
  15. How can you avoid new therapies being derailed by regulatory processes? This whitepaper presents successful strategies for peptide, oligonucleotide and mRNA therapeutic products.

    Poništi
  16. Poništi
  17. Gene therapies could revolutionize treatment of genetic disease, but how should the cost-effectiveness of these drugs be measured? We explore ->

    Poništi
  18. Why are format requirements for marketing authorisation applications still not consistent around the world? This whitepaper explores the latest gaps in harmonisation and the challenges behind them.

    Poništi
  19. Poništi
  20. How can you navigate the regulatory maze to get peptide, oligonucleotide and mRNA therapies to market? This whitepaper presents successful strategies & case studies.

    Poništi
  21. Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·